Emergent shares largely pricing in Teva approval, says Cantor Fitzgerald

The FDA on Friday granted Teva Pharmaceutical (TEVA) final approval for its generic version of Narcan, Cantor Fitzgerald analyst Brandon Folkes tells investors in a research note. The analyst views the announcement as largely anticipated following the expiration of Teva’s 30- month stay last month. Shares of Emergent BioSolutions (EBS) are down 18.7% since reporting Q4 earnings, largely driven by the anticipation of a final approval of Teva’s generic naloxone, says Folkes. While Friday’s approval is a negative and will continue to create an overhang on Emergent shares, the recent weakness has “adequately accounted for this overhang,” he contends. As such, Folkes keeps an Overweight rating on Emergent BioSolutions with a $75 price target.
https://thefly.com/landingPageNews.php?id=2894993